Search Search
sōna

Aspergillus GM Lateral Flow Assay

Invasive Aspergillosis is a serious threat—with over 30 million at-risk individuals annually1, early detection is critical.

Time matters. IMMY’s Aspergillus GM LFA delivers highly sensitive and specific results in just 45 minutes, enabling clinicians to test more often and initiate timely treatment.
1) https://en.fungaleducation.org/invasive-aspergillosis-mucormycosis/ 

Request Info
Product Documents
AspergillusGM_LFA_PNG_resized2

Specimen Types & Registrations

  • CE: Serum & BAL

Product Reference & Storage Conditions

  • AF2003
  • 2-30°C
Detect Early. Treat Fast. Save Lives.

Features & Benefits

Save Time
Results in just 45 MINUTES
Highly SENSITIVE & SPECIFIC
Test MORE OFTEN
Clinical Relevancy

Asp LFA Publication Findings2

The clinical performance of the IMMY sona Aspergillus Lateral Flow Assay in serum samples from cases classified as proven/probable/chronic IA/IFD (n=32) using EORTC/MSG criteria and control patients with no evidence of IFD (n=100).

In serum samples, the AGM LFA will correctly generate a positive result for 97% of patients with IA, and a negative result for 98% of patients without IA. The PPV shows that among patients with a positive AGM LFA result, the probability that they truly have IA is 94%. NPV shows that among patients with a negative AGM LFA result, the probability that they do not have IA is 99%.
2) Lewis W., et al. An evaluation of the performance of the IMMY sōna Aspergillus GM LFA when testing serum to aid in the diagnosis of IA. J Clin Micro. 2020; 00053-20.

Clinical Relevancy

Asp LFA Publication Findings3

The diagnostic performance of the IMMY sona Aspergillus Lateral Flow Assay in BAL samples from hematology patients classified as proven IPA (n=11) using EORTC/MSG criteria and control patients with no evidence of IPA (n=117).

In BAL samples, the AGM LFA will correctly generate a positive result for 91% of patients with IA, and a negative result for 92% of patients without IA. The NPV shows that among patients with a negative AGM LFA result, the probability that they do not have IA is 99%.

3) Mercier T, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2019.

Procedure

 

“ I am chief of mycology lab at HC/UFPR. We haved used CrAg LFA and Aspergillus LFA for more than 4 years with excellent performance. We are the reference for diagnosis and treatment of cryptococcosis in our state. IMMY provides robust tests for diagnosis of fungal infections. ”
Regielly Cognialli
Dr. Regielly Cognialli, PhD
Universidade Federal do Paraná

Real People, Real Results, Real Impact

Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies

Jenks JD, Mehta SR, Taplitz R, Law N, Reed SL, Hoenigl M. Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies. J Infect. 2019 Mar;78(3):249-259.

Respiratory specimens and the diagnostic accuracy of Aspergillus lateral flow assays (LFA-IMMY™): real-life data from a multicentre study.

Lass-Flörl C, Lo Cascio G, Nucci M, Camargo Dos Santos M, Colombo AL, Vossen M, Willinger B. Respiratory specimens and the diagnostic accuracy of Aspergillus lateral flow assays (LFA-IMMY™): real-life data from a multicentre study. Clin Microbiol Infect. 2019 Dec;25(12):1563.e1-1563.e3.

Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study

Mercier T, Dunbar A, de Kort E, et al. Lateral flow assays for diagnosing invasive pulmonary aspergillosis in adult hematology patients: A comparative multicenter study. Med Mycol. 2020;58(4):444-452.

The Aspergillus Lateral Flow Assay for the diagnosis of Invasive Aspergillosis: an Update

Jenks JD, Miceli MH, Prattes J, Mercier T, Hoenigl M. The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update [published online ahead of print, 2020 Dec 4]. Curr Fungal Infect Rep. 2020;1-6.

Evaluation of the Performance of the IMMY sōna Aspergillus Galactomannan Lateral Flow Assay When Testing Serum to Aid in Diagnosis of Invasive Aspergillosis

White PL, Price JS, Posso R, Cutlan-Vaughan M, Vale L, Backx M. Evaluation of the Performance of the IMMY sona Aspergillus Galactomannan Lateral Flow Assay When Testing Serum to Aid in Diagnosis of Invasive Aspergillosis. J Clin Microbiol. 2020;58(6):e00053-20.

Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis

Roman-Montes ACM, Martinez-Gamboa A, Diaz-Lomelí P, et al. Accuracy of galactomannan testing on tracheal aspirates in COVID-19-associated pulmonary aspergillosis [published online ahead of print, 2020 Nov 20]. Mycoses. 2020;10.1111/myc.13216.

 

Aspergillus Galactomannan LFA
50 tests
Ref: AF2003

Discover the Life-Saving Potential

Reach out to learn how IMMY’s Aspergillus GM Lateral Flow Assay can improve patient health with fast and accurate results.

Submit an Inquiry